ZIOPHARM Oncology, Inc. to Present Data at 2011 American Society of Clinical Oncology Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that Douglas J. Schwartzentruber, M.D., FACS, of the Indiana University Health Goshen Center for Cancer Care, will present clinical results from the first-ever treatment demonstrating control by an orally administered small molecule over the transgene-encoded expression of a therapeutic anti-cancer protein in humans, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3 - 7 in Chicago, IL. Results from the Phase Ib study of DC-RTS-IL-12 will be presented during the Developmental Therapeutics - Clinical Pharmacology and Immunotherapy Poster Session on Monday, June 6th from 8:00 am to 12:00 pm CT at McCormick Place, Hall A in Chicago, IL, in a poster titled: “Immunotherapy of advanced melanoma by intra-tumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand” (Poster # 1A).